13 October 2017 (Friday) - ASH Update

The American Society of Hematology sent me a few snippets today:


FEATURES
Mining the “Gold Rush” of Immunotherapy Clinical Trials
As the number of immunotherapy clinical trials grows, so do the obstacles and challenges – including the need to ensure meaningful results.

Entering A New Era of Immunotherapy
The first approval of a chimeric antigen receptor T-cell therapy marks a shift in the future of the immunotherapy field.
NEWLY APPROVED DRUGS
The Year in Drug Approvals
The excitement over immunotherapy for cancer treatment shows no signs of waning, with several agents approved by the U.S. Food and Drug Administration this year.
IN THE PIPELINE
The Immunotherapy Pipeline
Dozens of immunotherapeutic agents are under investigation for the treatment of malignant and non-malignant hematologic conditions.

All good stuff...

No comments:

Post a Comment